Prediction of Response to Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis

de Vlam Kurt; Coates Laura; Ogdie Alexis; Helliwell Philip; van der Heijde Desiree; Gladman Dafna; Wang Cunshan; Wu Joseph; Fallon Lara

首页> 外文期刊>The Journal of rheumatology >Prediction of Response to Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis

【24h】

Prediction of Response to Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis

机译：在有活跃的银屑病关节炎患者中预测对Tofacitinib，口腔janus激酶抑制剂的反应

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The Journal of rheumatology 》 |2019年第7期| 共1页
作者
de Vlam Kurt; Coates Laura; Ogdie Alexis; Helliwell Philip; van der Heijde Desiree; Gladman Dafna; Wang Cunshan; Wu Joseph; Fallon Lara;
展开▼
作者单位

UZ Leuven Leuven Belgium;

Univ Oxford Oxford England;

Univ Penn Dept Med Perelman Sch Med Div Rheumatol Philadelphia PA 19104 USA;

Univ Leeds Leeds W Yorkshire England;

Leiden Univ Med Ctr Leiden Netherlands;

Toronto Western Hosp Toronto ON Canada;

Pfizer Inc Groton CT 06340 USA;

Pfizer Inc Groton CT 06340 USA;

Pfizer Canada Inc Montreal PQ Canada;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类免疫性疾病 ;
关键词

相似文献

外文文献
中文文献
专利

1. Prediction of Response to Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis [J] . de Vlam Kurt, Coates Laura, Ogdie Alexis, The Journal of rheumatology . 2019 ,第7期

机译：在有活跃的银屑病关节炎患者中预测对Tofacitinib，口腔janus激酶抑制剂的反应
2. Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials [J] . Bethanie Wilkinson, David Gruben, Eun Bong Lee, Clinical and experimental rheumatology . 2016 ,第3期

机译：口服Janus激酶抑制剂tofacitinib对活动性类风湿关节炎患者报告的结局的影响：两项2期随机对照试验的结果
3. Baricitinib, an Oral Janus Kinase (JAK) 1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-BEACON Study [J] . Genovese Mark, Kremer Joel, Zamani Omid, The Journal of rheumatology . 2016 ,第6期

机译：活动性类风湿关节炎（RA）患者和对TNF抑制剂反应不足的患者口服Barustinib（JAK）1 / JAK2抑制剂：3期RA-BEACON研究的结果
4. Psoriatic arthritis Clinical improvement and correlation with hormone axes in etanercept-treated patients [C] . Fabiola Atzeni, Rainer H. Straub, Maurizio Cutolo, International Conference on the Neuroendocrine Immune Basis of the Rheumatic Diseases . 2010

机译：依托西普治疗患者患者临床改善及与激素轴相关性
5. Synthesis of Small Molecule Inhibitors of Janus Kinase 2, Phosphodiesterase IV, GABAA and NMDA receptors: Investigation of Mcmurry, Mannich and Chemoenzymatic Strategies [D] . Gali, Meghanath 2011

机译：Janus激酶2，磷酸二酯酶IV，GABAA和NMDA受体的小分子抑制剂的合成：Mcmurry，Mannich和化学酶策略的研究
6. Tofacitinib an oral Janus kinase inhibitor as monotherapy or with background methotrexate in Japanese patients with rheumatoid arthritis: an open-label long-term extension study [O] . Hisashi Yamanaka, Yoshiya Tanaka, Tsutomu Takeuchi, 2016

机译：Tofacitinib一种口服Janus激酶抑制剂在日本类风湿性关节炎患者中作为单一疗法或与甲氨蝶呤配合使用：一项长期开放性研究
7. SAT0469 Integrated efficacy analysis of tofacitinib, an oral janus kinase inhibitor, in patients with active psoriatic arthritis [O] . P Nash, LC Coates, R Fleischmann, 2017

机译：SAT0469活性银屑病关节炎患者中汤（Janus激酶抑制剂）的Tofacitinib综合疗效分析

Prediction of Response to Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis

著录项

相似文献

相关主题

期刊订阅